3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Hodgkin Disease
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
3
Primary Myelofibrosis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Glioblastoma
2
Anemia, Refractory, with Excess of Blasts
2
Neoplasms, Plasma Cell
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Extranodal NK-T-Cell
1
Hemoglobinuria, Paroxysmal
1
Gliosarcoma
1
Brain Neoplasms
1
Anemia, Aplastic
1
Interventions
Radiosurgery
114
Temozolomide
104
Bevacizumab
71
Radiotherapy
67
Magnetic Resonance Spectroscopy
67
Carboplatin
29
pembrolizumab
28
Irinotecan
26
Surgical Procedures, Operative
25
Radiation
23
Nivolumab
23
Etoposide
22
Magnetic Resonance Imaging
21
Ipilimumab
21
Erlotinib Hydrochloride
21
Cyclophosphamide
21
Surveys and Questionnaires
19
Aminolevulinic Acid
18
Specimen Handling
16
Pemetrexed
16
Mental Status and Dementia Tests
16
Cisplatin
16
Carmustine
15
Topotecan
14
Trastuzumab
13
Saline Solution
12
Neuropsychological Tests
12
Gefitinib
11
Filgrastim
11
Drug Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Brain Neoplasms
×
Basiliximab
×
Clear all
NCT00626483
2021-03-09
REGULATe
Duke University
Phase 1
Completed
34 enrolled